logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Opioids Market, By Product (Morphine, Fentanyl, Codeine, Meperidine) By Application (Diarrhea Suppression, Anesthesia, Pain Management, Cough Suppression, De-addiction) opportunities and forecast 2020-2026

  • DLR2195
  • 29 July, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Opioids, a group of narcotic pain-management drug are mostly used in developed countries. However the usage is restricted to prescribed users only. The product is used as an anesthesia, diarrhea suppressant, cough suppressant, and for the management of pain. Rising prevalence of diseases that results into chronic pain, such as postsurgical pain, cancer, lower back pain, arthritis, and fibromyalgia, is driving the market growth.

Although, the market is strictly regulated by the U.S. FDA due to reduce the cases of deaths registered in the country due to drug abuse. The organization has released specific guidelines for the companies to manufacture, store, market, and sell these products. Furthermore, In Jan 2019, Medicare established the new guidelines for opioid prescribing which are expected to affect Medicare Part D beneficiaries. Part D plans are expected to limit the early opioid dispensing to 7-day supply. Thus, these new guidelines are anticipated to limit the abuse rate in the country reducing the usage and hence acting as a market restraint.

On the other hand, once widely stigmatized, medical marijuana is projected as the potential antidote to the epidemic which is leading to over two-thirds of deaths annually in the U.S. Recent studies detected a substantial decrease in both drug abuse and overdose deaths from the prescription painkillers where medical marijuana has been legalized. Biotech and pharma companies believe that the products will become the predominant opioid substitute for the chronic pain management and will provide a wide variety of various other beneficial therapies.

Segment Overview

Fentanyl, an extended release opioid commanded the major market share of opioids by product in 2018 owing to high usage in chronic pain management. However, the misuse and abuse of these drugs have caused a serious public health crisis in major countries. As a result, the U.S. FDA in Sept 2018, released final Opioid Analgesic Risk Evaluation and Mitigation Strategy for ER and IR opioids. The plan will help reduce overall exposure to the drugs and consequently reduce the addiction rate.

On the basis of application, pain management commanded the major market share in 2018. However, product usage for the pain is anticipated to decline over the period owing to the implementation of the new regulatory framework. The new guideline has been designed by CDC for prescribing opioids for the chronic pain. According to the guideline, it has been suggested that non-opioid therapy or treatment should be preferred for various chronic pain other than the palliative, active cancer, end-of-life care.

Regional Overview

North America commanded the major market share in 2018 as the consumption is highest in the region. Though, the region is expected to witness decline in the market share in the coming years owing to the rising government efforts to combat crisis in the U.S. for instance; recently, the FDA discontinued wide variety of the opioids from market to limit abuse. Such as, Percocet (oxycodone), and Vicodin (hydrocodone) the widely prescribed opioids. Furthermore, the decline in prescriptions have been observed in recent years. In 2017, the prescription rate of these drugs reduced by 10.2% from the 2016. Hence, these factors are expected to limit the growth of the opioids market over the forecast period.

Furthermore, awareness initiatives by the government are further expected to reduce the growth rate of the opioids usage during the forecast period. For Instance; in June 2018, the government launched public awareness campaign to combat the addiction. In addition, few of the opioid products including Purdue Pharma’ OxyContin have been discontinued in the U.S. and Canada. However, countries in Asia Pacific are expected to witness the fastest growth during the forecast period as the companies such as Purdue Pharma are now shifting their focus to these countries with an aim to strengthen their market position.

Competitor overview

Some of the key market players are Purdue Pharma L.P.; Allergan; West-Ward Pharmaceuticals Corporation; Janssen Pharmaceuticals, Inc.; Pfizer, Inc.; Egalet Corporation; and Sun Pharmaceutical Industries Limited. Key players are majorly focusing on expanding their business units in different regions to increase the market share.

For Instance, Purdue Pharma is entering rapidly into Latin America, Asia, and Middle East and Africa. The company is focusing on organizing awareness programs where the doctors are advised to prescribe painkillers to help the patients overcome opiophobia.

Key Players
  1. Purdue Pharma L.P
  2. West-Ward Pharmaceuticals Corporation
  3. Janssen Pharmaceuticals, Inc.
  4. West-Ward Pharmaceuticals Corporation
  5. Sanofi-Aventis S.A.
  6. Pfizer, Inc.
  7. ALLERGAN (Actavis)
  8. Sun Pharmaceutical Industries Limited
  9. Grunenthal Gmbh
Market Segmentation

By Product
  • Morphine
  • Fentanyl
  • Codeine
  • Meperidine
By Application
  • Diarrhea Suppression
  • Anesthesia, Pain Management
  • Cough Suppression
  • De-addiction
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


Table of Contents

    1 Report Prologue 13

      2 Market Introduction 16

      • 2.1 Definition 17
      • 2.2 Scope of the Study 17
      • 2.3 Research Objective 17
      • 2.4 Assumptions & Limitations 17
        • 2.4.1 Assumptions 17
        • 2.4.2 Limitations 17
        • 2.4.3 Market Structure 18

      3 Research Methodology 19

      • 3.1 Primary Research Methodology 20
      • 3.2 Secondary Research Methodology 21
      • 3.3 Market Size Estimation 22
      • 3.4 Forecast Model 22

      4 Market Dynamics 23

      • 4.1 Introduction 24
      • 4.2 Drivers 25
        • 4.2.1 Increasing use of opioids for disease condition causing chronic pains such as cancers, arthritis, lower back pain, and fibromyalgia 25
        • 4.2.2 Favorable reimbursement policies for palliative care in developed regions 25
        • 4.2.3 Substantial rise in road accidents, trauma, and surgical procedures 25
      • 4.3 Restraints 26
        • 4.3.1 Rising addiction and death cases due to overdose of opioid 26
      • 4.4 Opportunities 26
        • 4.4.1 Reconsideration of prescribing opioid analgesics due to rising awareness about opioids misuse, abuse, and overdose has prompted many stakeholders 26

      5 Market Factor Analysis 27

      • 5.1 Porter’s Five Forces Model 28
        • 5.1.1 Bargaining Power of Suppliers 28
        • 5.1.2 Bargaining Power of Buyers 29
        • 5.1.3 Threat of New Entrants 29
        • 5.1.4 Threat of Substitutes 29
        • 5.1.5 Intensity of Rivalry 29
      • 5.2 Value Chain Analysis 30
        • 5.2.1 Research &Development 30
        • 5.2.2 Manufacturing 30
        • 5.2.3 Distribution 30
        • 5.2.4 Marketing & Sales 31
        • 5.2.5 Post-Sales Monitoring 31
      • 5.3 Demand & Supply: Gap Analysis 31
      • 5.4 Pricing Analysis 31

      6 Global Opioids Market, by Product 32

      • 6.1 Overview 33
      • 6.2 Extended-Release/Long-Acting Opioid 34
      • 6.3 Immediate-Release/Short-Acting Opioid 36

      7 Global Opioids Market, by Application 38

      • 7.1 Overview 39
      • 7.2 Pain Relief 40
      • 7.3 Anesthesia 41
      • 7.4 Cough Suppression 42
      • 7.5 Diarrhoea Suppression 43
      • 7.6 Deaddiction 43

      8 Global Opioids Market, by End User 44

      • 8.1 Overview 45
      • 8.2 Hospitals & Clinics 46
      • 8.3 Pharmacies 47
      • 8.4 Academic Research Institutes 47

      9 Global Opioids Market, by Region 49

      • 9.1 Overview 50
      • 9.2 Americas 51
        • 9.2.1 North America 55
        • 9.2.2 US 58
        • 9.2.3 Canada 61
        • 9.2.4 Latin America 64
      • 9.3 Europe 68
        • 9.3.1 Western Europe 72
        • 9.3.2 Germany 76
        • 9.3.3 UK 79
        • 9.3.4 France 82
        • 9.3.5 Spain 85
        • 9.3.6 Italy 88
        • 9.3.7 Rest of Western Europe 91
        • 9.3.8 Eastern Europe 94
      • 9.4 Asia-Pacific 97
        • 9.4.1 China 101
        • 9.4.2 Japan 104
        • 9.4.3 India 107
        • 9.4.4 Australia 110
        • 9.4.5 South Korea 113
        • 9.4.6 Rest of Asia-Pacific 116
      • 9.5 Middle East & Africa 120
        • 9.5.1 Middle East 124
        • 9.5.2 Africa 127

      10 Competitive Landscape 130

      • 10.1 Company Market Share Analysis 131
        • 10.1.1 Overview 131

      11 Company Profile 132

      • 11.1 Sanofi SA 133
        • 11.1.1 Company Overview 133
        • 11.1.2 Financial Overview 133
        • 11.1.3 Products/Services Offered 133
        • 11.1.4 Key Developments 134
        • 11.1.5 SWOT Analysis 134
        • 11.1.6 Key Strategy 134
      • 11.2 Pfizer Inc 135
        • 11.2.1 Company Overview 135
        • 11.2.2 Financial Overview 135
        • 11.2.3 Products/Services Offered 136
        • 11.2.4 Key Developments 136
        • 11.2.5 SWOT Analysis 136
        • 11.2.6 Key Strategy 136
      • 11.3 Boehringer Ingelheim GmbH 137
        • 11.3.1 Company Overview 137
        • 11.3.2 Financial Overview 137
        • 11.3.3 Products/Services Offered 137
        • 11.3.4 Key Developments 138
        • 11.3.5 SWOT Analysis 138
        • 11.3.6 Key Strategy 138
      • 11.4 Teva Pharmaceutical Industries Ltd 139
        • 11.4.1 Company Overview 139
        • 11.4.2 Financial Overview 139
        • 11.4.3 Products/Services Offered 140
        • 11.4.4 Key Developments 140
        • 11.4.5 SWOT Analysis 141
        • 11.4.6 Key Strategy 141
      • 11.5 Allergan Inc. 142
        • 11.5.1 Company Overview 142
        • 11.5.2 Financial Overview 142
        • 11.5.3 Products/Services Offered 143
        • 11.5.4 SWOT Analysis 143
        • 11.5.5 Key Developments 143
        • 11.5.6 Key strategy 143
      • 11.6 Purdue Pharma L.P. 144
        • 11.6.1 Company Overview 144
        • 11.6.2 Financial Overview 144
        • 11.6.3 Products/Services Offered 144
        • 11.6.4 Key Developments 144
        • 11.6.5 SWOT Analysis 145
        • 11.6.6 Key Strategy 145
      • 11.7 West-Ward Pharmaceuticals Corporation 146
        • 11.7.1 Company Overview 146
        • 11.7.2 Financial Overview 146
        • 11.7.3 Products/Services Offered 146
        • 11.7.4 Key Developments 147
        • 11.7.5 SWOT Analysis 147
        • 11.7.6 Key Strategy 147
      • 11.8 Sun Pharmaceutical Industries Ltd 148
        • 11.8.1 Company Overview 148
        • 11.8.2 Financial Overview 148
        • 11.8.3 Products/Services Offered 149
        • 11.8.4 Key Developments 149
        • 11.8.5 SWOT Analysis 149
        • 11.8.6 Key Strategy 149
      • 11.9 Egalet Corporation 150
        • 11.9.1 Company Overview 150
        • 11.9.2 Financial Overview 150
        • 11.9.3 Products/Services Offered 150
        • 11.9.4 Key Developments 150
        • 11.9.5 SWOT Analysis 150
        • 11.9.6 Key Strategy 150
      • 11.10 Janssen Global Services, LLC 151
        • 11.10.1 Company Overview 151
        • 11.10.2 Financial Overview 151
        • 11.10.3 Products/Services Offered 152
        • 11.10.4 Key Developments 152
        • 11.10.5 SWOT Analysis 152
        • 11.10.6 Key Strategy 152
      • 11.11 Vertice Pharma LLC 153
        • 11.11.1 Company Overview 153
        • 11.11.2 Financial Overview 153
        • 11.11.3 Products/Services Offered 153
        • 11.11.4 Key Developments 153
        • 11.11.5 SWOT Analysis 153
        • 11.11.6 Key Strategy 153
      • 11.12 Mallinckrodt 154
        • 11.12.1 Company Overview 154
        • 11.12.2 Financial Overview 154
        • 11.12.3 Products/Services Offered 154
        • 11.12.4 Key Developments 155
        • 11.12.5 SWOT Analysis 155
        • 11.12.6 Key Strategy 155

      12 Appendix 156

      Report You Might be Interested